Plasma from systemic lupus patients compromises cholesterol homeostasis: A potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease

Rheumatology International

Volumn 30, Issue 5, 2010, Pages 591-598

  Reiss, Allison B ^a   Anwar, Kamran ^a   Merrill, Joan T ^b   Chan, Edwin S L ^c   Awadallah, Nahel W ^c   Cronstein, Bruce N ^c   Belmont, H Michael ^c   Belilos, Elise ^a   Rosenblum, Gary ^a   Belostocki, Kristina ^a   Bonetti, Lois ^a   Hasneen, Kowser ^c   Carsons, Steven E ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cholesterol; Foam cells; Lupus erythematosus; Macrophage scavenger receptor; Systemic

Indexed keywords

CHOLESTEROL; CHOLESTEROL 27 HYDROXYLASE; LOW DENSITY LIPOPROTEIN; OXYGENASE; UNCLASSIFIED DRUG;

ADULT; AORTA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; AUTOIMMUNITY; BLOOD ANALYSIS; CELL TRANSFORMATION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; FOAM CELL; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING;

ADOLESCENT; ADULT; ATHEROSCLEROSIS; AUTOIMMUNITY; CASE-CONTROL STUDIES; CELLS, CULTURED; CHOLESTEROL; CYTOCHROME P-450 CYP27A1; DOWN-REGULATION; ENDOTHELIAL CELLS; FEMALE; FOAM CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HOMEOSTASIS; HUMANS; INTERFERON-GAMMA; LIPOPROTEINS, LDL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MONOCYTES; RECEPTORS, INTERFERON; RISK FACTORS; RNA, MESSENGER; YOUNG ADULT;

EID: 77951024622     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1020-6     Document Type: Article

References (51)

1. Asanuma Y, Oeser A, Shintani AK et al (2003) Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2407-2415
2. Roman MJ, Shanker BA, Davis A et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2399-2406
3. Nikpour M, Urowitz MB, Gladman DD (2005) Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 31:329-354
4. Schattner A, Liang MH (2003) The cardiovascular burden of lupus: a complex challenge. Arch Intern Med 163:1507-1510
5. Bruce IN, Gladman DD, Urowitz MB (2000) Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 26:257-278
6. Manzi S, Meilahn EN, Rairie JE et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408-415
7. Badui E, Garcia-Rubi D, Robles E et al (1985) Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 36:431-441
8. Moder KG, Miller TD, Tazelaar HD (1999) Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74:275-284
9. Caracciolo EA, Marcu CB, Ghantous A, Donohue TJ, Hutchinson G (2004) Coronary vasculitis with acute myocardial infarction in a young woman with systemic lupus erythematosus. J Clin Rheumatol 10:66-68
10. Nobrega TP, Klodas E, Breen JF, Liggett SP, Higano ST, Reeder GS (1996) Giant coronary artery aneurysms and myocardial infarction in a patient with systemic lupus erythematosus. Cathet Cadiovasc Diagn 39:75-79
11. Sharma AK, Farb A, Maniar P, Ajani AE, Castagna M, Virmani R, Suddath W, Lindsay J (2003) Spontaneous coronary artery dissection in a patient with systemic lupus erythematosis. Hawaii Med J 62:248-253
12. Sella EM, Sato EI, Leite WA, Oliveira Filho JA, Barbieri A (2003) Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann Rheum Dis 62:1066-1070 (Pubitemid 37323570)
13. Soubrier M, Mathieu S, Dubost JJ (2007) Atheroma and systemic lupus erythematosus. Joint Bone Spine 74:566-570
14. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135-1143
15. Roman MJ, Salmon JE, Sobel R, Lockshin MD, Sammaritano L, Schwartz JE, Devereux RB (2001) Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid syndrome. Am J Cardiol 87:663-666
16. Gezer S (2003) Antiphospholipid syndrome. Dis Mon 49:696-741
17. Lahita RG, Rivkin E, Cavanagh I et al (1993) Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36:1566-1574
18. Vaarala O, Alfthan G, Jauhiainen M et al (1993) Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341:923-925
19. Garrido JA, Peromingo J, Sesma P et al (1994) More about the link between thrombosis and atherosclerosis in autoimmune diseases: triglycerides and risk for thrombosis in patients with antiphospholipid antibodies. J Rheumatol 21:2394
20. Esdaile JM, Abrahamowicz M, Grodzicky T et al (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44:2331-2337
21. Fukumoto S, Tsumagari T, Kinjo M et al (1987) Coronary atherosclerosis in patients with systemic lupus erythematosus at autopsy. Acta Pathol Jpn 37:1-9
22. Haider YS, Roberts WC (1981) Coronary arterial disease in systemic lupus erythematosus. Am J Med 70:775-781
23. Reiss AB, Awadallah NW, Malhotra S et al (2001) Immune complexes and interferon-γ decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J Lipid Res 42:1913-1922
24. Reiss AB, Patel CA, Rahman MM et al (2004) Interferon-gamma impedes reverse cholesterol transport and promotes foam cell transformation in THP-1 human monocytes/macrophages. Med Sci Monit 10:BR420-BR425
25. Hall EA, Ren S, Hylemon PB, Redford K, del Castillo A, Gil G, Pandak WM (2005) Mitochondrial cholesterol transport: a possible target in the management of hyperlipidemia. Lipids 40:1237-1244
26. Reiss AB, Martin KO, Javitt NB, Martin DW, Grossi EA, Galloway AC (1994) Sterol 27-hydroxylase: high levels of activity in vascular endothelium. J Lipid Res 35:1026-1030
27. Reiss AB, Martin KO, Rojer DE, Iyer S, Grossi EA, Galloway AC, Javitt NB (1997) Sterol 27-hydroxylase: expression in human arterial endothelium. J Lipid Res 38:1254-1260
28. Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease. N Engl J Med 326:242-250
29. Badimon L, Badimon JJ, Penny W, Webster MW, Chesebro JH, Fuster V (1992) Endothelium and atherosclerosis. J Hypertens Suppl 10:S43-S50
30. Zeiher AM, Drexler H, Saurbier B, Just H (1993) Endotheliummediated coronary blood Xow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 92:652-662
31. Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini AR, Sinzinger H, Mannarino E (2000) Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 36:617-621
32. Bjorkhem I (2002) Do oxysterols control cholesterol homeostasis. J Clin Invest 110:725-730
33. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, RothWeld NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classiWcation of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277
34. Chan ES, Zhang H, Fernandez P, Edelman SD, Pillinger MH, Ragolia L, Palaia T, Carsons SE, Reiss AB (2007) Effects of COX inhibition on cholesterol eZux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Res Ther 9:R4
35. Cali JJ, Hsieh C, Francke U, Russell DW (1991) Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 266:7779-7783
36. Reiss AB, Glass AD (2006) Atherosclerosis: immune and inflammatory aspects. J Invest Med 54:123-131
37. Moore KJ, Freeman MW (2006) Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 26:1702-1711
38. McMahon M, Hahn BH (2007) Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 19:633-639 (Pubitemid 350236815)
39. Al-Janadi M, Al-Balla S, Al-Dalaan A, Raziuddin S (1993) Cytokine proWle in systemic lupus erythematosus, rheumatoid arthritis and other rheumatic diseases. J Clin Immunol 13:58-67 (Pubitemid 23047997)
40. Aringer M, Smolen JS (2004) Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 13:344-347 (Pubitemid 38788494)
41. Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, Stein CM (2006) Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 33:539-545 (Pubitemid 43334577)
42. Gautier EL, Huby T, Ouzilleau B, Doucet C, Saint-Charles F, Gremy G, Chapman MJ, Lesnik P (2007) Enhanced immune system activation and arterial inflammation accelerates atherosclerosis in lupus-prone mice. Arterioscler Thromb Vasc Biol 27:1625-1631 (Pubitemid 46986119)
43. Reiss AB, Wan DW, Anwar K, Merrill JT, Wirkowski PA, Shah N, Cronstein BN, Chan ES, Carsons SE (2009) Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp Biol Med 234:354-360
44. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C (1997) IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 99:2752-2761 (Pubitemid 27259823)
45. Li H, Freeman MW, Libby P (1995) Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. J Clin Invest 95:122-133
46. Whitman SC, Ravisankar P, Elam H, Daugherty A (2000) Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E¡/¡ mice. Am J Pathol 157:1819-1824
47. Lund E, Andersson O, Zhang J, Babiker A, Ahlborg G, Diczfalusy U, Einarsson K, Sjovall J, Bjorkhem I (1996) Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Arterioscler Thromb Vasc Biol 16:208-212 (Pubitemid 26056238)
48. Reiss AB, Anwar F, Chan ESL, Anwar K (2009) Disruption of cholesterol eZux by coxib medications and inflammatory processes: link to increased cardiovascular risk. J Invest Med [Epub ahead of print]
49. Reiss AB, Carsons SE, Rao S, Edelman SD, Zhang H, Fernandez P, Cronstein BN, Chan ES (2008) Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in THP-1 human monocytes/macrophages. Arthritis Rheum 58:3675-3683
50. Kabokov AE, Tertov VV, Saenko VA, Poverenny AM, Orekhov AN (1992) The atherogenic effects of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol 6:214-220
51. Matsuura E, Lopez LR (2004) Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis? Clin Dev Immunol 11:103-111 (Pubitemid 38955066)